Antibody subclass repertoire and graft outcome following solid organ transplantation

Frontiers in Immunology

Volumn 7, Issue OCT, 2016, Pages

  Valenzuela, Nicole M ^a,b   Hickey, Michelle J ^a,b   Reed, Elaine F ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HLA donor specific antibodies; IgG subclass; Transplant

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; ALLOANTIBODY; ANAPHYLATOXIN; BIOLOGICAL MARKER; CD16 ANTIGEN; CD32 ANTIGEN; CD64 ANTIGEN; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3D RECEPTOR; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYCLOSPORIN; DECAY ACCELERATING FACTOR; FC RECEPTOR; HLA ANTIBODY; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; LEUKOCYTE ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; OPSONIN; RAPAMYCIN;

ANTIBODY AFFINITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY MEDIATED REJECTION; ANTIGEN PRESENTING CELL; CELL INFILTRATION; CELL MEDIATED CYTOTOXICITY; CELL MIGRATION; CELL PROLIFERATION; COMPLEMENT DEPENDENT CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE REARRANGEMENT; GRAFT DYSFUNCTION; HUMAN; HYPERACUTE GRAFT REJECTION; IMMUNOGLOBULIN G DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; NEISSERIA MENINGITIDIS; OPSONIZATION; ORGAN TRANSPLANTATION; PARTIAL AGONISM; PHAGOCYTOSIS; PREECLAMPSIA; REVIEW; SURGICAL INJURY; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME;

EID: 84997471468     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00433     Document Type: Review

References (193)

1. Sellares J, de Freitas DG, Mengel M, Reeve J, Einecke G, Sis B, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant (2012) 12(2):388-99. doi:10.1111/j.1600-6143.2011.03840.x.
2. Wiebe C, Gibson IW, Blydt-Hansen TD, Pochinco D, Birk PE, Ho J, et al. Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody. Am J Transplant (2015) 15(11):2921-30. doi:10.1111/ajt.13347.
3. Everly MJ, Rebellato LM, Haisch CE, Ozawa M, Parker K, Briley KP, et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation (2013) 95(3):410-7. doi:10.1097/TP.0b013e31827d62e3.
4. Smith JD, Banner NR, Hamour IM, Ozawa M, Goh A, Robinson D, et al. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant (2011) 11(2):312-9. doi:10.1111/j.1600-6143.2010.03383.x.
5. Irving CA, Carter V, Gennery AR, Parry G, Griselli M, Hasan A, et al. Effect of persistent versus transient donor-specific HLA antibodies on graft outcomes in pediatric cardiac transplantation. J Heart Lung Transplant (2015) 34(10):1310-7. doi:10.1016/j.healun.2015.05.001.
6. Tran A, Fixler D, Huang R, Meza T, Lacelle C, Das BB. Donor-specific HLA alloantibodies: impact on cardiac allograft vasculopathy, rejection, and survival after pediatric heart transplantation. J Heart Lung Transplant (2016) 35(1):87-91. doi:10.1016/j.healun.2015.08.008.
7. O'Leary JG, Kaneku H, Demetris AJ, Marr JD, Shiller SM, Susskind BM, et al. Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss. Liver Transpl (2014) 20(2):218-27. doi:10.1002/lt.23788.
8. Cuadrado A, San Segundo D, Lopez-Hoyos M, Crespo J, Fabrega E. Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation. World J Gastroenterol (2015) 21(39):11016-26. doi:10.3748/wjg.v21.i39.11016.
9. Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Lavayssiere L, Esposito L, et al. De novo donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients. Transpl Int (2015) 28(12):1371-82. doi:10.1111/tri.12654.
10. Kauke T, Kneidinger N, Martin B, Dick A, Schneider C, Schramm R, et al. Bronchiolitis obliterans syndrome due to donor-specific HLA-antibodies. Tissue Antigens (2015) 86(3):178-85. doi:10.1111/tan.12626.
11. Roux A, Bendib Le Lan I, Holifanjaniaina S, Thomas KA, Hamid AM, Picard C, et al. Antibody-mediated rejection in lung transplantation: clinical outcomes and donor-specific antibody characteristics. Am J Transplant (2016) 16(4):1216-28. doi:10.1111/ajt.13589.
12. Niederhaus SV, Leverson GE, Lorentzen DF, Robillard DJ, Sollinger HW, Pirsch JD, et al. Acute cellular and antibody-mediated rejection of the pancreas allograft: incidence, risk factors and outcomes. Am J Transplant (2013) 13(11):2945-55. doi:10.1111/ajt.12443.
13. Adebiyi OO, Gralla J, Klem P, Freed B, Davis S, Wiseman A, et al. Clinical significance of pre-transplant donor specific antibodies in the setting of negative cell-based flow cytometry crossmatching in kidney transplant recipients. Am J Transplant (2016). doi:10.1111/ajt.13848.
14. Abu-Elmagd KM, Wu G, Costa G, Lunz J, Martin L, Koritsky DA, et al. Preformed and de novo donor specific antibodies in visceral transplantation: long-term outcome with special reference to the liver. Am J Transplant (2012) 12(11):3047-60. doi:10.1111/j.1600-6143.2012.04237.x.
15. Cheng EY, Kaneku H, Farmer DG. The role of donor-specific antibodies in intestinal transplantation: experience at the University of California Los Angeles and Literature Review. Clin Transpl (2014):153-9.
16. Haas M. An updated Banffschema for diagnosis of antibody-mediated rejection in renal allografts. Curr Opin Organ Transplant (2014) 19(3):315-22. doi:10.1097/MOT.0000000000000072.
17. Haas M, Sis B, Racusen LC, Solez K, Glotz D, Colvin RB, et al. Banff2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 14(2):272-83. doi:10.1111/ajt.12590.
18. Berry GJ, Angelini A, Burke MM, Bruneval P, Fishbein MC, Hammond E, et al. The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: evolution and current status (2005-2011). J Heart Lung Transplant (2011) 30(6):601-11. doi:10.1016/j.healun.2011.02.015.
19. Kobashigawa J, Crespo-Leiro MG, Ensminger SM, Reichenspurner H, Angelini A, Berry G, et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant (2011) 30(3):252-69. doi:10.1016/j.healun.2010.11.003.
20. Levine DJ, Glanville AR, Aboyoun C, Belperio J, Benden C, Berry GJ, et al. Antibody-mediated rejection of the lung: a consensus report of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant (2016) 35(4):397-406. doi:10.1016/j.healun.2016.01.1223.
21. Drachenberg CB, Torrealba JR, Nankivell BJ, Rangel EB, Bajema IM, Kim DU, et al. Guidelines for the diagnosis of antibody-mediated rejection in pancreas allografts-updated Banffgrading schema. Am J Transplant (2011) 11(9):1792-802. doi:10.1111/j.1600-6143.2011.03670.x.
22. O'Leary JG, Cai J, Freeman R, Banuelos N, Hart B, Johnson M, et al. Proposed diagnostic criteria for chronic antibody-mediated rejection in liver allografts. Am J Transplant (2016) 16(2):603-14. doi:10.1111/ajt.13476.
23. Wiebe C, Nevins TE, Robiner WN, Thomas W, Matas AJ, Nickerson PW. The synergistic effect of class II HLA epitope-mismatch and nonadherence on acute rejection and graft survival. Am J Transplant (2015) 15(8):2197-202. doi:10.1111/ajt.13341.
24. Panigrahi A, Gupta N, Siddiqui JA, Margoob A, Bhowmik D, Guleria S, et al. Post transplant development of MICA and anti-HLA antibodies is associated with acute rejection episodes and renal allograft loss. Hum Immunol (2007) 68(5):362-7. doi:10.1016/j.humimm.2007.01.006.
25. Zou Y, Stastny P, Susal C, Dohler B, Opelz G. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med (2007) 357(13):1293-300. doi:10.1056/NEJMoa067160.
26. Narayan S, Tsai EW, Zhang Q, Wallace WD, Reed EF, Ettenger RB. Acute rejection associated with donor-specific anti-MICA antibody in a highly sensitized pediatric renal transplant recipient. Pediatr Transplant (2011) 15(1):E1-7. doi:10.1111/j.1399-3046.2010.01407.x.
27. Zhang Q, Cecka JM, Gjertson DW, Ge P, Rose ML, Patel JK, et al. HLA and MICA: targets of antibody-mediated rejection in heart transplantation. Transplantation (2011) 91(10):1153-8. doi:10.1097/TP.0b013e3182157d60.
28. Stastny P, Lavingia B, Fixler DE, Yancy CW, Ring WS. Antibodies against donor human leukocyte antigens and the outcome of cardiac allografts in adults and children. Transplantation (2007) 84(6):738-45. doi:10.1097/01.tp.0000281918.51138.3f.
29. Wiebe C, Gibson IW, Blydt-Hansen TD, Karpinski M, Ho J, Storsley LJ, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant (2012) 12(5):1157-67. doi:10.1111/j.1600-6143.2012.04013.x.
30. Loupy A, Lefaucheur C, Vernerey D, Prugger C, Duong van Huyen JP, Mooney N, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med (2013) 369(13):1215-26. doi:10.1056/NEJMoa1302506.
31. Aalberse RC, Stapel SO, Schuurman J, Rispens T. Immunoglobulin G4: an odd antibody. Clin Exp Allergy (2009) 39(4):469-77. doi:10.1111/j.1365-2222.2009.03207.x.
32. Berkowska MA, Driessen GJ, Bikos V, Grosserichter-Wagener C, Stamatopoulos K, Cerutti A, et al. Human memory B cells originate from three distinct germinal center-dependent and-independent maturation pathways. Blood (2011) 118(8):2150-8. doi:10.1182/blood-2011-04-345579.
33. Devey ME, Bleasdale-Barr KM, Bird P, Amlot PL. Antibodies of different human IgG subclasses show distinct patterns of affinity maturation after immunization with keyhole limpet haemocyanin. Immunology (1990) 70(2):168-74.
34. Galson JD, Clutterbuck EA, Truck J, Ramasamy MN, Munz M, Fowler A, et al. BCR repertoire sequencing: different patterns of B-cell activation after two meningococcal vaccines. Immunol Cell Biol (2015) 93(10):885-95. doi:10.1038/icb.2015.57.
35. Cooper LJ, Robertson D, Granzow R, Greenspan NS. Variable domain-identical antibodies exhibit IgG subclass-related differences in affinity and kinetic constants as determined by surface plasmon resonance. Mol Immunol (1994) 31(8):577-84. doi:10.1016/0161-5890(94)90165-1.
36. McCloskey N, Turner MW, Steffner P, Owens R, Goldblatt D. Human constant regions influence the antibody binding characteristics of mouse-human chimeric IgG subclasses. Immunology (1996) 88(2):169-73. doi:10.1111/j.1365-2567.1996.tb00001.x.
37. Tian X, Vestergaard B, Thorolfsson M, Yang Z, Rasmussen HB, Langkilde AE. In-depth analysis of subclass-specific conformational preferences of IgG antibodies. IUCrJ (2015) 2(Pt 1):9-18. doi:10.1107/S205225251402209X.
38. Tang Y, Lou J, Alpaugh RK, Robinson MK, Marks JD, Weiner LM. Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J Immunol (2007) 179(5):2815-23. doi:10.4049/jimmunol.179.5.2815.
39. Mazor Y, Yang C, Borrok MJ, Ayriss J, Aherne K, Wu H, et al. Enhancement of immune effector functions by modulating IgG's intrinsic affinity for target antigen. PLoS One (2016) 11(6):e0157788. doi:10.1371/journal.pone.0157788.
40. Stapleton NM, Andersen JT, Stemerding AM, Bjarnarson SP, Verheul RC, Gerritsen J, et al. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat Commun (2011) 2:599. doi:10.1038/ncomms1608.
41. Migot-Nabias F, Lokossou AG, Vigan-Womas I, Guitard E, Guillotte M, Noukpo JM, et al. Combined effects of Gm or Km immunoglobulin allotypes and age on antibody responses to Plasmodium falciparum VarO rosetting variant in Benin. Microbes Infect (2011) 13(8-9):771-5. doi:10.1016/j.micinf.2011.04.001.
42. Einarsdottir H, Ji Y, Visser R, Mo C, Luo G, Scherjon S, et al. H435-containing immunoglobulin G3 allotypes are transported efficiently across the human placenta: implications for alloantibody-mediated diseases of the newborn. Transfusion (2014) 54(3):665-71. doi:10.1111/trf.12334.
43. Jin YP, Singh RP, Du ZY, Rajasekaran AK, Rozengurt E, Reed EF. Ligation of HLA class I molecules on endothelial cells induces phosphorylation of Src, paxillin, and focal adhesion kinase in an actin-dependent manner. J Immunol (2002) 168(11):5415-23. doi:10.4049/jimmunol.168.11.5415.
44. Jindra PT, Zhang X, Mulder A, Claas F, Veale J, Jin YP, et al. Anti-HLA antibodies can induce endothelial cell survival or proliferation depending on their concentration. Transplantation (2006) 82(1 Suppl):S33-5. doi:10.1097/01.tp.0000231447.34240.3c.
45. Yamakuchi M, Kirkiles-Smith NC, Ferlito M, Cameron SJ, Bao C, Fox-Talbot K, et al. Antibody to human leukocyte antigen triggers endothelial exocytosis. Proc Natl Acad Sci U S A (2007) 104(4):1301-6. doi:10.1073/pnas.0602035104.
46. Jindra PT, Hsueh A, Hong L, Gjertson D, Shen XD, Gao F, et al. Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts. J Immunol (2008) 180(4):2214-24. doi:10.4049/jimmunol.180.4.2214.
47. Jindra PT, Jin YP, Rozengurt E, Reed EF. HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol (2008) 180(4):2357-66. doi:10.4049/jimmunol.180.4.2357.
48. Morrell CN, Murata K, Swaim AM, Mason E, Martin TV, Thompson LE, et al. In vivo platelet-endothelial cell interactions in response to major histocompatibility complex alloantibody. Circ Res (2008) 102(7):777-85. doi:10.1161/CIRCRESAHA.107.170332.
49. 4 to stimulate endothelial cell proliferation and migration. Sci Signal (2010) 3(149):ra85. doi:10.1126/scisignal.2001158.
50. Li F, Zhang X, Jin YP, Mulder A, Reed EF. Antibody ligation of human leukocyte antigen class I molecules stimulates migration and proliferation of smooth muscle cells in a focal adhesion kinase-dependent manner. Hum Immunol (2011) 72(12):1150-9. doi:10.1016/j.humimm.2011.09.004.
51. Ziegler ME, Jin YP, Young SH, Rozengurt E, Reed EF. HLA class I-mediated stress fiber formation requires ERK1/2 activation in the absence of an increase in intracellular Ca2+ in human aortic endothelial cells. Am J Physiol Cell Physiol (2012) 303(8):C872-82. doi:10.1152/ajpcell.00199.2012.
52. Valenzuela NM, Hong L, Shen XD, Gao F, Young SH, Rozengurt E, et al. Blockade of p-selectin is sufficient to reduce MHC I antibody-elicited monocyte recruitment in vitro and in vivo. Am J Transplant (2013) 13(2):299-311. doi:10.1111/ajt.12016.
53. Valenzuela NM, Mulder A, Reed EF. HLA class I antibodies trigger increased adherence of monocytes to endothelial cells by eliciting an increase in endothelial P-selectin and, depending on subclass, by engaging FcgammaRs. J Immunol (2013) 190(12):6635-50. doi:10.4049/jimmunol.1201434.
54. Jin YP, Valenzuela NM, Ziegler ME, Rozengurt E, Reed EF. Everolimus inhibits anti-HLA I antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus. Am J Transplant (2014) 14(4):806-19. doi:10.1111/ajt.12669.
55. Claus R, Hausmann S, Zavazava N, Walzel H, Schulze HA, Kohler H, et al. In vitro effects of solubilized HLA-DR-role in immunoregulation? Cell Immunol (1994) 155(2):476-85. doi:10.1006/cimm.1994.1139.
56. Tiedemann RE, Fraser JD. Cross-linking of MHC class II molecules by staphylococcal enterotoxin A is essential for antigen-presenting cell and T cell activation. J Immunol (1996) 157(9):3958-66.
57. Guo W, Mourad W, Charron D, Al-Daccak R. Ligation of MHC class II molecules differentially upregulates TNF beta gene expression in B cell lines of different MHC class II haplotypes. Hum Immunol (1999) 60(4):312-22. doi:10.1016/S0198-8859(98)00131-1.
58. Meguro M, Nishimura F, Ohyama H, Takashiba S, Murayama Y, Matsushita S. Ligation of IFN-gamma-induced HLA-DR molecules on fibroblasts induces RANTES expression via c-Jun N-terminal kinase (JNK) pathway. Cytokine (2003) 22(5):107-15. doi:10.1016/S1043-4666(03)00123-6.
59. Kriegel MA, Adam-Klages S, Gabler C, Blank N, Schiller M, Scheidig C, et al. Anti-HLA-DR-triggered monocytes mediate in vitro T cell anergy. Int Immunol (2008) 20(4):601-13. doi:10.1093/intimm/dxn019.
60. Taflin C, Favier B, Charron D, Glotz D, Mooney N. Study of the allogeneic response induced by endothelial cells expressing HLA class II after lentiviral transduction. Methods Mol Biol (2013) 960:461-72. doi:10.1007/978-1-62703-218-6_34.
61. Lion J, Taflin C, Cross AR, Robledo-Sarmiento M, Mariotto E, Savenay A, et al. HLA class II antibody activation of endothelial cells promotes Th17 and disrupts regulatory T lymphocyte expansion. Am J Transplant (2016) 16(5):1408-20. doi:10.1111/ajt.13644.
62. Sis B, Jhangri GS, Bunnag S, Allanach K, Kaplan B, Halloran PF. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant (2009) 9(10):2312-23. doi:10.1111/j.1600-6143.2009.02761.x.
63. Gunther J, Kill A, Becker MO, Heidecke H, Rademacher J, Siegert E, et al. Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients. Arthritis Res Ther (2014) 16(2):R65. doi:10.1186/ar4503.
64. Kill A, Tabeling C, Undeutsch R, Kuhl AA, Gunther J, Radic M, et al. Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis. Arthritis Res Ther (2014) 16(1):R29. doi:10.1186/ar4457.
65. LaMarca B, Parrish MR, Wallace K. Agonistic autoantibodies to the angiotensin II type I receptor cause pathophysiologic characteristics of preeclampsia. Gend Med (2012) 9(3):139-46. doi:10.1016/j.genm.2012.03.001.
66. Li H, Yu X, Cicala MV, Mantero F, Benbrook A, Veitla V, et al. Prevalence of angiotensin II type 1 receptor (AT1R)-activating autoantibodies in primary aldosteronism. J Am Soc Hypertens (2015) 9(1):15-20. doi:10.1016/j.jash.2014.10.009.
67. Dragun D, Muller DN, Brasen JH, Fritsche L, Nieminen-Kelha M, Dechend R, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med (2005) 352(6):558-69. doi:10.1056/NEJMoa035717.
68. Urban M, Slavcev A, Gazdic T, Ivak P, Besik J, Netuka I. The impact of angiotensin II type 1 receptor antibodies on post-heart transplantation outcome in Heart Mate II bridged recipients. Interact Cardiovasc Thorac Surg (2016) 22(3):292-7. doi:10.1093/icvts/ivv344.
69. Jackson AM, Sigdel TK, Delville M, Hsieh SC, Dai H, Bagnasco S, et al. Endothelial cell antibodies associated with novel targets and increased rejection. J Am Soc Nephrol (2015) 26(5):1161-71. doi:10.1681/ASN.2013121277.
70. Stein R, Qu Z, Chen S, Solis D, Hansen HJ, Goldenberg DM. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab. Blood (2006) 108(8):2736-44. doi:10.1182/blood-2006-04-017921.
71. Baldwin WM, Ota H, Rodriguez ER. Complement in transplant rejection: diagnostic and mechanistic considerations. Springer Semin Immunopathol (2003) 25(2):181-97. doi:10.1007/s00281-003-0133-3.
72. Rosner T, Lohse S, Peipp M, Valerius T, Derer S. Epidermal growth factor receptor targeting IgG3 triggers complement-mediated lysis of decay-accelerating factor expressing tumor cells through the alternative pathway amplification loop. J Immunol (2014) 193(3):1485-95. doi:10.4049/jimmunol.1400329.
73. Esposito A, Suedekum B, Liu J, An F, Lass J, Strainic MG, et al. Decay accelerating factor is essential for successful corneal engraftment. Am J Transplant (2010) 10(3):527-34. doi:10.1111/j.1600-6143.2009.02961.x.
74. Pavlov V, Raedler H, Yuan S, Leisman S, Kwan WH, Lalli PN, et al. Donor deficiency of decay-accelerating factor accelerates murine T cell-mediated cardiac allograft rejection. J Immunol (2008) 181(7):4580-9. doi:10.4049/jimmunol.181.7.4580.
75. Raedler H, Yang M, Lalli PN, Medof ME, Heeger PS. Primed CD8(+) T-cell responses to allogeneic endothelial cells are controlled by local complement activation. Am J Transplant (2009) 9(8):1784-95. doi:10.1111/j.1600-6143.2009.02723.x.
76. Gonzalez-Stawinski GV, Tan CD, Smedira NG, Starling RC, Rodriguez ER. Decay-accelerating factor expression may provide immunoprotection against antibody-mediated cardiac allograft rejection. J Heart Lung Transplant (2008) 27(4):357-61. doi:10.1016/j.healun.2008.01.008.
77. Vidarsson G, van Der Pol WL, van Den Elsen JM, Vile H, Jansen M, Duijs J, et al. Activity of human IgG and IgA subclasses in immune defense against Neisseria meningitidis serogroup B. J Immunol (2001) 166(10):6250-6. doi:10.4049/jimmunol.166.10.6250.
78. Rahimi S, Qian Z, Layton J, Fox-Talbot K, Baldwin WM III, Wasowska BA. Non-complement-and complement-activating antibodies synergize to cause rejection of cardiac allografts. Am J Transplant (2004) 4(3):326-34. doi:10.1111/j.1600-6143.2004.00334.x.
79. Dangl JL, Wensel TG, Morrison SL, Stryer L, Herzenberg LA, Oi VT. Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies. EMBO J (1988) 7(7):1989-94.
80. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med (1969) 280(14):735-9. doi:10.1056/NEJM196904032801401.
81. Nakashima S, Qian Z, Rahimi S, Wasowska BA, Baldwin WM III. Membrane attack complex contributes to destruction of vascular integrity in acute lung allograft rejection. J Immunol (2002) 169(8):4620-7. doi:10.4049/jimmunol.169.8.4620.
82. Deuel TF, Senior RM, Huang JS, Griffin GL. Chemotaxis of monocytes and neutrophils to platelet-derived growth factor. J Clin Invest (1982) 69(4):1046-9. doi:10.1172/JCI110509.
83. Haynes DR, Harkin DG, Bignold LP, Hutchens MJ, Taylor SM, Fairlie DP. Inhibition of C5a-induced neutrophil chemotaxis and macrophage cytokine production in vitro by a new C5a receptor antagonist. Biochem Pharmacol (2000) 60(5):729-33. doi:10.1016/S0006-2952(00)00361-0.
84. Foreman KE, Vaporciyan AA, Bonish BK, Jones ML, Johnson KJ, Glovsky MM, et al. C5a-induced expression of P-selectin in endothelial cells. J Clin Invest (1994) 94(3):1147-55. doi:10.1172/JCI117430.
85. Jane-Wit D, Manes TD, Yi T, Qin L, Clark P, Kirkiles-Smith NC, et al. Alloantibody and complement promote T cell-mediated cardiac allograft vasculopathy through noncanonical nuclear factor-kappaB signaling in endothelial cells. Circulation (2013) 128(23):2504-16. doi:10.1161/CIRCULATIONAHA.113.002972.
86. Jane-Wit D, Surovtseva YV, Qin L, Li G, Liu R, Clark P, et al. Complement membrane attack complexes activate noncanonical NF-kappaB by forming an Akt+ NIK+ signalosome on Rab5+ endosomes. Proc Natl Acad Sci U S A (2015) 112(31):9686-91. doi:10.1073/pnas.1503535112.
87. Hirohashi T, Uehara S, Chase CM, DellaPelle P, Madsen JC, Russell PS, et al. Complement independent antibody-mediated endarteritis and transplant arteriopathy in mice. Am J Transplant (2010) 10(3):510-7. doi:10.1111/j.1600-6143.2009.02958.x.
88. Qin L, Li G, Kirkiles-Smith N, Clark P, Fang C, Wang Y, et al. Complement C5 inhibition reduces T cell-mediated allograft vasculopathy caused by both alloantibody and ischemia reperfusion injury in humanized mice. Am J Transplant (2016). doi:10.1111/ajt.13834.
89. Gonzalez SF, Lukacs-Kornek V, Kuligowski MP, Pitcher LA, Degn SE, Turley SJ, et al. Complement-dependent transport of antigen into B cell follicles. J Immunol (2010) 185(5):2659-64. doi:10.4049/jimmunol.1000522.
90. Kwan WH, van der Touw W, Heeger PS. Complement regulation of T cell immunity. Immunol Res (2012) 54(1-3):247-53. doi:10.1007/s12026-012-8327-1.
91. Sheen JH, Heeger PS. Effects of complement activation on allograft injury. Curr Opin Organ Transplant (2015) 20(4):468-75. doi:10.1097/MOT.0000000000000216.
92. Chen G, Sequeira F, Tyan DB. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol (2011) 72(10):849-58. doi:10.1016/j.humimm.2011.07.001.
93. Otten HG, Verhaar MC, Borst HP, Hene RJ, van Zuilen AD. Pretransplant donor-specific HLA class-I and-II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant (2012) 12(6):1618-23. doi:10.1111/j.1600-6143.2011.03985.x.
94. Crespo M, Torio A, Mas V, Redondo D, Perez-Saez MJ, Mir M, et al. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter? Transpl Immunol (2013) 29(1-4):28-33. doi:10.1016/j.trim.2013.07.002.
95. Freitas MC, Rebellato LM, Ozawa M, Nguyen A, Sasaki N, Everly M, et al. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation (2013) 95(9):1113-9. doi:10.1097/TP.0b013e3182888db6.
96. Wahrmann M, Exner M, Regele H, Derfler K, Kormoczi GF, Lhotta K, et al. Flow cytometry based detection of HLA alloantibody mediated classical complement activation. J Immunol Methods (2003) 275(1-2):149-60. doi:10.1016/S0022-1759(03)00012-7.
97. Smith JD, Hamour IM, Banner NR, Rose ML. C4d fixing, luminex binding antibodies-a new tool for prediction of graft failure after heart transplantation. Am J Transplant (2007) 7(12):2809-15. doi:10.1111/j.1600-6143.2007.01991.x.
98. Lachmann N, Todorova K, Schulze H, Schonemann C. Systematic comparison of four cell-and Luminex-based methods for assessment of complement-activating HLA antibodies. Transplantation (2013) 95(5):694-700. doi:10.1097/TP.0b013e31827b3dc3.
99. Wahrmann M, Hlavin G, Fischer G, Marinova L, Schwaiger E, Horl WH, et al. Modified solid-phase alloantibody detection for improved crossmatch prediction. Hum Immunol (2013) 74(1):32-40. doi:10.1016/j.humimm.2012.10.012.
100. Bohmig GA, Kikic Z, Wahrmann M, Eskandary F, Aliabadi AZ, Zlabinger GJ, et al. Detection of alloantibody-mediated complement activation: a diagnostic advance in monitoring kidney transplant rejection? Clin Biochem (2016) 49(4-5):394-403. doi:10.1016/j.clinbiochem.2015.05.024.
101. Sicard A, Ducreux S, Rabeyrin M, Couzi L, McGregor B, Badet L, et al. Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. J Am Soc Nephrol (2015) 26(2):457-67. doi:10.1681/ASN.2013101144.
102. Comoli P, Cioni M, Tagliamacco A, Quartuccio G, Innocente A, Fontana I, et al. Acquisition of C3d-binding activity by de novo donor-specific HLA antibodies correlates with graft loss in nonsensitized pediatric kidney recipients. Am J Transplant (2016) 16(7):2106-16. doi:10.1111/ajt.13700.
103. Dieplinger G, Everly MJ, Rebellato LM, Haisch CE, Briley KP, Bolin P, et al. Changes in successive measures of de novo donor-specific anti-human leukocyte antigen antibodies intensity and the development of allograft dysfunction. Transplantation (2014) 98(10):1097-104. doi:10.1097/TP.0000000000000190.
104. Zeevi A, Lunz J, Feingold B, Shullo M, Bermudez C, Teuteberg J, et al. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients. J Heart Lung Transplant (2013) 32(1):98-105. doi:10.1016/j.healun.2012.09.021.
105. Chin C, Chen G, Sequeria F, Berry G, Siehr S, Bernstein D, et al. Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart Lung Transplant (2011) 30(2):158-63. doi:10.1016/j.healun.2010.08.020.
106. Yabu JM, Higgins JP, Chen G, Sequeira F, Busque S, Tyan DB. C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation (2011) 91(3):342-7. doi:10.1097/TP.0b013e318203fd26.
107. Sutherland SM, Chen G, Sequeira FA, Lou CD, Alexander SR, Tyan DB. Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant (2012) 16(1):12-7. doi:10.1111/j.1399-3046.2011.01599.x.
108. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science (2005) 310(5753):1510-2. doi:10.1126/science.1118948.
109. Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity (2006) 24(1):19-28. doi:10.1016/j.immuni.2005.11.010.
110. Sanders LA, van de Winkel JG, Rijkers GT, Voorhorst-Ogink MM, de Haas M, Capel PJ, et al. Fc gamma receptor IIa (CD32) heterogeneity in patients with recurrent bacterial respiratory tract infections. J Infect Dis (1994) 170(4):854-61. doi:10.1093/infdis/170.4.854.
111. Pawlik A, Florczak M, Bak L, Domanski L, Rozanski J, Dabrowska-Zamojcin E, et al. The Fc gamma RIIa polymorphism in patients with acute kidney graft rejection. Ann Transplant (2003) 8(4):24-6.
112. Bazilio AP, Viana VS, Toledo R, Woronik V, Bonfa E, Monteiro RC. Fc gamma RIIa polymorphism: a susceptibility factor for immune complex-mediated lupus nephritis in Brazilian patients. Nephrol Dial Transplant (2004) 19(6):1427-31. doi:10.1093/ndt/gfh121.
113. Bournazos S, Woof JM, Hart SP, Dransfield I. Functional and clinical consequences of Fc receptor polymorphic and copy number variants. Clin Exp Immunol (2009) 157(2):244-54. doi:10.1111/j.1365-2249.2009.03980.x.
114. Mellor JD, Brown MP, Irving HR, Zalcberg JR, Dobrovic A. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol (2013) 6:1. doi:10.1186/1756-8722-6-1.
115. Wu J, Lin R, Huang J, Guan W, Oetting WS, Sriramarao P, et al. Functional Fcgamma receptor polymorphisms are associated with human allergy. PLoS One (2014) 9(2):e89196. doi:10.1371/journal.pone.0089196.
116. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood (2009) 113(16):3716-25. doi:10.1182/blood-2008-09-179754.
117. Karagiannis P, Gilbert AE, Josephs DH, Ali N, Dodev T, Saul L, et al. IgG4 subclass antibodies impair antitumor immunity in melanoma. J Clin Invest (2013) 123(4):1457-74. doi:10.1172/JCI65579.
118. Miltenburg AM, Meijer-Paape ME, Weening JJ, Daha MR, van Es LA, van der Woude FJ. Induction of antibody-dependent cellular cytotoxicity against endothelial cells by renal transplantation. Transplantation (1989) 48(4):681-8.
119. Yard B, Spruyt-Gerritse M, Claas F, Thorogood J, Bruijn JA, Paape ME, et al. The clinical significance of allospecific antibodies against endothelial cells detected with an antibody-dependent cellular cytotoxicity assay for vascular rejection and graft loss after renal transplantation. Transplantation (1993) 55(6):1287-93. doi:10.1097/00007890-199306000-00015.
120. Akiyoshi T, Hirohashi T, Alessandrini A, Chase CM, Farkash EA, Neal Smith R, et al. Role of complement and NK cells in antibody mediated rejection. Hum Immunol (2012) 73(12):1226-32. doi:10.1016/j.humimm.2012.07.330.
121. Kohei N, Tanaka T, Tanabe K, Masumori N, Dvorina N, Valujskikh A, et al. Natural killer cells play a critical role in mediating inflammation and graft failure during antibody-mediated rejection of kidney allografts. Kidney Int (2016) 89(6):1293-306. doi:10.1016/j.kint.2016.02.030.
122. Hidalgo LG, Sis B, Sellares J, Campbell PM, Mengel M, Einecke G, et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant (2010) 10(8):1812-22. doi:10.1111/j.1600-6143.2010.03201.x.
123. Hidalgo LG, Sellares J, Sis B, Mengel M, Chang J, Halloran PF. Interpreting NK cell transcripts versus T cell transcripts in renal transplant biopsies. Am J Transplant (2012) 12(5):1180-91. doi:10.1111/j.1600-6143.2011.03970.x.
124. Florey OJ, Johns M, Esho OO, Mason JC, Haskard DO. Antiendothelial cell antibodies mediate enhanced leukocyte adhesion to cytokine-activated endothelial cells through a novel mechanism requiring cooperation between FcγRIIa and CXCR1/2. Blood (2007) 109(9):3881-9. doi:10.1182/blood-2006-08-044669.
125. Valenzuela NM, Trinh KR, Mulder A, Morrison SL, Reed EF. Monocyte recruitment by HLA IgG-activated endothelium: the relationship between IgG subclass and FcgammaRIIa polymorphisms. Am J Transplant (2015) 15(6):1502-18. doi:10.1111/ajt.13174.
126. Honger G, Hopfer H, Arnold ML, Spriewald BM, Schaub S, Amico P. Pretransplant IgG subclasses of donor-specific human leukocyte antigen antibodies and development of antibody-mediated rejection. Transplantation (2011) 92(1):41-7. doi:10.1097/TP.0b013e31821cdf0d.
127. Kaneku H, O'Leary JG, Taniguchi M, Susskind BM, Terasaki PI, Klintmalm GB. Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transpl (2012) 18(8):984-92. doi:10.1002/lt.23451.
128. Lowe D, Higgins R, Zehnder D, Briggs DC. Significant IgG subclass heterogeneity in HLA-specific antibodies: implications for pathogenicity, prognosis, and the rejection response. Hum Immunol (2013) 74(5):666-72. doi:10.1016/j.humimm.2013.01.008.
129. Khovanova N, Daga S, Shaikhina T, Krishnan N, Jones J, Zehnder D, et al. Subclass analysis of donor HLA-specific IgG in antibody-incompatible renal transplantation reveals a significant association of IgG4 with rejection and graft failure. Transpl Int (2015) 28(12):1405-15. doi:10.1111/tri.12648.
130. Lefaucheur C, Viglietti D, Bentlejewski C, Duong van Huyen JP, Vernerey D, Aubert O, et al. IgG Donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury. J Am Soc Nephrol (2016) 27(1):293-304. doi:10.1681/ASN.2014111120.
131. Jackson AM, Lucas DP, Melancon JK, Desai NM. Clinical relevance and IgG subclass determination of non-HLA antibodies identified using endothelial cell precursors isolated from donor blood. Transplantation (2011) 92(1):54-60. doi:10.1097/TP.0b013e31821b60e9.
132. Griffiths EJ, Nelson RE, Dupont PJ, Warrens AN. Skewing of pretransplant anti-HLA class I antibodies of immunoglobulin G isotype solely toward immunoglobulin G1 subclass is associated with poorer renal allograft survival. Transplantation (2004) 77(11):1771-3. doi:10.1097/01.TP.0000129408.07168.40.
133. Lefaucheur C, Loupy A, Hill GS, Andrade J, Nochy D, Antoine C, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol (2010) 21(8):1398-406. doi:10.1681/ASN.2009101065.
134. Regan J, Monteiro F, Speiser D, Kalil J, Pouletty P, Buelow R. Pretransplant rejection risk assessment through enzyme-linked immunosorbent assay analysis of anti-HLA class I antibodies. Am J Kidney Dis (1996) 28(1):92-8. doi:10.1016/S0272-6386(96)90136-5.
135. Monteiro F, Mineiro C, Rodrigues H, de Paula FJ, Kalil J. Pretransplant and posttransplant monitoring of anti-HLA class I IgG1 antibodies by ELISA identifies patients at high risk of graft loss. Transplant Proc (1997) 29(1-2):1433-4. doi:10.1016/S0041-1345(96)00541-6.
136. Gao ZH, McAlister VC, Wright JR Jr, McAlister CC, Peltekian K, MacDonald AS. Immunoglobulin-G subclass antidonor reactivity in transplant recipients. Liver Transpl (2004) 10(8):1055-9. doi:10.1002/lt.20154.
137. Kushihata F, Watanabe J, Mulder A, Claas F, Scornik JC. Human leukocyte antigen antibodies and human complement activation: role of IgG subclass, specificity, and cytotoxic potential. Transplantation (2004) 78(7):995-1001. doi:10.1097/01.TP.0000136966.63957.E2.
138. Lobashevsky A, Rosner K, Goggins W, Higgins N. Subtypes of immunoglobulin (Ig)-G antibodies against donor class II HLA and cross-match results in three kidney transplant candidates. Transpl Immunol (2010) 23(1-2):81-5. doi:10.1016/j.trim.2010.03.003.
139. Everly MJ, Rebellato LM, Haisch CE, Briley KP, Bolin P, Kendrick WT, et al. Impact of IgM and IgG3 anti-HLA alloantibodies in primary renal allograft recipients. Transplantation (2014) 97(5):494-501. doi:10.1097/01.TP.0000441362.11232.48.
140. Aalberse RC, van der Gaag R, van Leeuwen J. Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J Immunol (1983) 130(2):722-6.
141. Schaub S, Honger G, Amico P. The complexity of the humoral immune response against HLA antigens. Transpl Int (2014) 27(3):249-50. doi:10.1111/tri.12230.
142. Arnold ML, Ntokou IS, Doxiadis II, Spriewald BM, Boletis JN, Iniotaki AG. Donor-specific HLA antibodies: evaluating the risk for graft loss in renal transplant recipients with isotype switch from complement fixing IgG1/IgG3 to noncomplement fixing IgG2/IgG4 anti-HLA alloantibodies. Transpl Int (2014) 27(3):253-61. doi:10.1111/tri.12206.
143. Zwirner NW, Marcos CY, Mirbaha F, Zou Y, Stastny P. Identification of MICA as a new polymorphic alloantigen recognized by antibodies in sera of organ transplant recipients. Hum Immunol (2000) 61(9):917-24. doi:10.1016/S0198-8859(00)00162-2.
144. Sumitran-Holgersson S, Wilczek HE, Holgersson J, Soderstrom K. Identification of the nonclassical HLA molecules, mica, as targets for humoral immunity associated with irreversible rejection of kidney allografts. Transplantation (2002) 74(2):268-77. doi:10.1097/00007890-200207270-00019.
145. Jurcevic S, Ainsworth ME, Pomerance A, Smith JD, Robinson DR, Dunn MJ, et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation (2001) 71(7):886-92. doi:10.1097/00007890-200104150-00011.
146. Joosten SA, Sijpkens YW, van Ham V, Trouw LA, van der Vlag J, van den Heuvel B, et al. Antibody response against the glomerular basement membrane protein agrin in patients with transplant glomerulopathy. Am J Transplant (2005) 5(2):383-93. doi:10.1111/j.1600-6143.2005.00690.x.
147. Vermehren D, Sumitran-Holgersson S. Isolation of precursor endothelial cells from peripheral blood for donor-specific crossmatching before organ transplantation. Transplantation (2002) 74(11):1479-86. doi:10.1097/01.TP.0000040003.89413.A6.
148. Smith JD, Brunner VM, Jigjidsuren S, Hamour IM, McCormack AM, Banner NR, et al. Lack of effect of MICA antibodies on graft survival following heart transplantation. Am J Transplant (2009) 9(8):1912-9. doi:10.1111/j.1600-6143.2009.02722.x.
149. Alvarez-Marquez A, Aguilera I, Gentil MA, Caro JL, Bernal G, Fernandez Alonso J, et al. Donor-specific antibodies against HLA, MICA, and GSTT1 in patients with allograft rejection and C4d deposition in renal biopsies. Transplantation (2009) 87(1):94-9. doi:10.1097/TP.0b013e31818bd790.
150. Reinsmoen NL, Lai CH, Heidecke H, Haas M, Cao K, Ong G, et al. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation (2010) 90(12):1473-7. doi:10.1097/TP.0b013e3181fd97f1.
151. Dragun D. Agonistic antibody-triggered stimulation of angiotensin II type 1 receptor and renal allograft vascular pathology. Nephrol Dial Transplant (2007) 22(7):1819-22. doi:10.1093/ndt/gfm072.
152. Philogene MC, Bagnasco S, Kraus ES, Montgomery RA, Dragun D, Leffell MS, et al. Anti-angiotensin II type 1 receptor and anti-endothelial cell antibodies: a cross-sectional analysis of pathological findings in allograft biopsies. Transplantation (2016). doi:10.1097/TP.0000000000001231.
153. Breimer ME, Rydberg L, Jackson AM, Lucas DP, Zachary AA, Melancon JK, et al. Multicenter evaluation of a novel endothelial cell crossmatch test in kidney transplantation. Transplantation (2009) 87(4):549-56. doi:10.1097/TP.0b013e3181949d4e.
154. Sigdel TK, Sarwal MM. Moving beyond HLA: a review of nHLA antibodies in organ transplantation. Hum Immunol (2013) 74(11):1486-90. doi:10.1016/j.humimm.2013.07.001.
155. O'Leary JG, Kaneku H, Banuelos N, Jennings LW, Klintmalm GB, Terasaki PI. Impact of IgG3 subclass and C1q-fixing donor-specific HLA alloantibodies on rejection and survival in liver transplantation. Am J Transplant (2015) 15(4):1003-13. doi:10.1111/ajt.13153.
156. Barrett DJ, Ayoub EM. IgG2 subclass restriction of antibody to pneumococcal polysaccharides. Clin Exp Immunol (1986) 63(1):127-34.
157. Hjelholt A, Christiansen G, Sorensen US, Birkelund S. IgG subclass profiles in normal human sera of antibodies specific to five kinds of microbial antigens. Pathog Dis (2013) 67(3):206-13. doi:10.1111/2049-632X.12034.
158. Kemeny DM, MacKenzie-Mills M, Harries MG, Youlten LJ, Lessof MH. Antibodies to purified bee venom proteins and peptides. II. A detailed study of changes in IgE and IgG antibodies to individual bee venom antigens. J Allergy Clin Immunol (1983) 72(4):376-85. doi:10.1016/0091-6749(83)90503-1.
159. Schumacher MJ, Egen NB, Tanner D. Neutralization of bee venom lethality by immune serum antibodies. Am J Trop Med Hyg (1996) 55(2):197-201.
160. Ottesen EA, Skvaril F, Tripathy SP, Poindexter RW, Hussain R. Prominence of IgG4 in the IgG antibody response to human filariasis. J Immunol (1985) 134(4):2707-12.
161. Kurniawan A, Yazdanbakhsh M, van Ree R, Aalberse R, Selkirk ME, Partono F, et al. Differential expression of IgE and IgG4 specific antibody responses in asymptomatic and chronic human filariasis. J Immunol (1993) 150(9):3941-50.
162. Malisan F, Briere F, Bridon JM, Harindranath N, Mills FC, Max EE, et al. Interleukin-10 induces immunoglobulin G isotype switch recombination in human CD40-activated naive B lymphocytes. J Exp Med (1996) 183(3):937-47. doi:10.1084/jem.183.3.937.
163. Fear DJ, McCloskey N, O'Connor B, Felsenfeld G, Gould HJ. Transcription of Ig germline genes in single human B cells and the role of cytokines in isotype determination. J Immunol (2004) 173(7):4529-38. doi:10.4049/jimmunol.173.7.4529.
164. Pene J, Gauchat JF, Lecart S, Drouet E, Guglielmi P, Boulay V, et al. Cutting edge: IL-21 is a switch factor for the production of IgG1 and IgG3 by human B cells. J Immunol (2004) 172(9):5154-7. doi:10.4049/jimmunol.172.9.5154.
165. Avery DT, Bryant VL, Ma CS, de Waal Malefyt R, Tangye SG. IL-21-induced isotype switching to IgG and IgA by human naive B cells is differentially regulated by IL-4. J Immunol (2008) 181(3):1767-79. doi:10.4049/jimmunol.181.3.1767.
166. Hornick P, Lechler R. Direct and indirect pathways of alloantigen recognition: relevance to acute and chronic allograft rejection. Nephrol Dial Transplant (1997) 12(9):1806-10. doi:10.1093/ndt/12.9.1806.
167. Afzali B, Lombardi G, Lechler RI. Pathways of major histocompatibility complex allorecognition. Curr Opin Organ Transplant (2008) 13(4):438-44. doi:10.1097/MOT.0b013e328309ee31.
168. Brennan TV, Jaigirdar A, Hoang V, Hayden T, Liu FC, Zaid H, et al. Preferential priming of alloreactive T cells with indirect reactivity. Am J Transplant (2009) 9(4):709-18. doi:10.1111/j.1600-6143.2009.02578.x.
169. Garrod KR, Liu FC, Forrest LE, Parker I, Kang SM, Cahalan MD. NK cell patrolling and elimination of donor-derived dendritic cells favor indirect alloreactivity. J Immunol (2010) 184(5):2329-36. doi:10.4049/jimmunol.0902748.
170. Bradley JA, Mowat AM, Bolton EM. Processed MHC class I alloantigen as the stimulus for CD4+ T-cell dependent antibody-mediated graft rejection. Immunol Today (1992) 13(11):434-8. doi:10.1016/0167-5699(92)90069-J.
171. Morton AL, Bell EB, Bolton EM, Marshall HE, Roadknight C, McDonagh M, et al. CD4+ T cell-mediated rejection of major histocompatibility complex class I-disparate grafts: a role for alloantibody. Eur J Immunol (1993) 23(9):2078-84. doi:10.1002/eji.1830230906.
172. Pettigrew GJ, Lovegrove E, Bradley JA, Maclean J, Bolton EM. Indirect T cell allorecognition and alloantibody-mediated rejection of MHC class I-disparate heart grafts. J Immunol (1998) 161(3):1292-8.
173. Taylor AL, Negus SL, Negus M, Bolton EM, Bradley JA, Pettigrew GJ. Pathways of helper CD4 T cell allorecognition in generating alloantibody and CD8 T cell alloimmunity. Transplantation (2007) 83(7):931-7. doi:10.1097/01.tp.0000257960.07783.e3.
174. Conlon TM, Cole JL, Motallebzadeh R, Harper I, Callaghan CJ, Bolton EM, et al. Unlinked memory helper responses promote long-lasting humoral alloimmunity. J Immunol (2012) 189(12):5703-12. doi:10.4049/jimmunol.1202257.
175. Shiu KY, McLaughlin L, Rebollo-Mesa I, Zhao J, Semik V, Cook HT, et al. B-lymphocytes support and regulate indirect T-cell alloreactivity in individual patients with chronic antibody-mediated rejection. Kidney Int (2015) 88(3):560-8. doi:10.1038/ki.2015.100.
176. Valujskikh AN. B cells regulate antidonor T-cell reactivity in transplantation. Kidney Int (2015) 88(3):444-6. doi:10.1038/ki.2015.171.
177. Pizzo HP, Ettenger RB, Gjertson DW, Reed EF, Zhang J, Gritsch HA, et al. Sirolimus and tacrolimus coefficient of variation is associated with rejection, donor-specific antibodies, and nonadherence. Pediatr Nephrol (2016). doi:10.1007/s00467-016-3422-5.
178. Luca ME, Paul LC, van Der Wal AM, Bruijn JA, de Heer E. Treatment with mycophenolate mofetil attenuates the development of Heymann nephritis. Exp Nephrol (2000) 8(2):77-83. doi:10.1159/000020652.
179. Ramos MA, Pinera C, Setien MA, Buelta L, de Cos MA, de Francisco AL, et al. Modulation of autoantibody production by mycophenolate mofetil: effects on the development of SLE in (NZB x NZW)F1 mice. Nephrol Dial Transplant (2003) 18(5):878-83. doi:10.1093/ndt/gfg034.
180. Heidt S, Roelen DL, Eijsink C, Eikmans M, van Kooten C, Claas FH, et al. Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help. Clin Exp Immunol (2010) 159(2):199-207. doi:10.1111/j.1365-2249.2009.04051.x.
181. De Bruyne R, Bogaert D, De Ruyck N, Lambrecht BN, Van Winckel M, Gevaert P, et al. Calcineurin inhibitors dampen humoral immunity by acting directly on naive B cells. Clin Exp Immunol (2015) 180(3):542-50. doi:10.1111/cei.12604.
182. Borriello F, Sethna MP, Boyd SD, Schweitzer AN, Tivol EA, Jacoby D, et al. B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Immunity (1997) 6(3):303-13. doi:10.1016/S1074-7613(00)80333-7.
183. Kim EJ, Kwun J, Gibby AC, Hong JJ, Farris AB III, Iwakoshi NN, et al. Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. Am J Transplant (2014) 14(1):59-69. doi:10.1111/ajt.12526.
184. Ibrahim S, Jakobs F, Kittur D, Hess A, Linsley PS, Sanfilippo F, et al. CTLA4Ig inhibits alloantibody responses to repeated blood transfusions. Blood (1996) 88(12):4594-600.
185. Ibrahim S, Xu R, Burdick JF, Baldwin W, Sanfilippo F, Kittur DS. CTLA4Ig inhibits humoral and cellular immune responses to concordant xenografts. Transplant Proc (1996) 28(2):715-6.
186. Pestana JO, Grinyo JM, Vanrenterghem Y, Becker T, Campistol JM, Florman S, et al. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant (2012) 12(3):630-9. doi:10.1111/j.1600-6143.2011.03914.x.
187. Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L, et al. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med (2016) 374(4):333-43. doi:10.1056/NEJMoa1506027.
188. Leibler C, Matignon M, Pilon C, Montespan F, Bigot J, Lang P, et al. Kidney transplant recipients treated with belatacept exhibit increased naive and transitional B cells. Am J Transplant (2014) 14(5):1173-82. doi:10.1111/ajt.12721.
189. Espinosa JR, Samy KP, Kirk AD. Memory T cells in organ transplantation: progress and challenges. Nat Rev Nephrol (2016) 12(6):339-47. doi:10.1038/nrneph.2016.9.
190. Westra J, van Assen S, Wilting KR, Land J, Horst G, de Haan A, et al. Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients. Clin Exp Immunol (2014) 178(1):40-7. doi:10.1111/cei.12390.
191. Limon JJ, So L, Jellbauer S, Chiu H, Corado J, Sykes SM, et al. mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition. Proc Natl Acad Sci U S A (2014) 111(47):E5076-85. doi:10.1073/pnas.1407104111.
192. Siemasko K, Chong AS, Jack HM, Gong H, Williams JW, Finnegan A. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J Immunol (1998) 160(4):1581-8.
193. Rousvoal G, Si MS, Lau M, Zhang S, Berry GJ, Flores MG, et al. Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy. Transpl Int (2006) 19(12):1014-21. doi:10.1111/j.1432-2277.2006.00387.x.